Clinical data for Genmab’s ADC Rina-S is mounting, as the pharma company plans more late-stage trials.
BMS and BioNTech will jointly develop and commercialise the asset that targets both PD-L1 and VEGF-A.
The FDA set a PDUFA date in late 2025 as ziftomenib led to significant disease response in patients with common subtype of AML.
Sanofi has committed to pay $129 per share in cash on closure.
The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study.
Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.
